Insulet Co. (NASDAQ:PODD) CAO Lauren Budden Sells 915 Shares of Stock

Insulet Co. (NASDAQ:PODD) CAO Lauren Budden sold 915 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This represents a 13.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Insulet Price Performance

Shares of PODD opened at $273.47 on Thursday. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The company’s fifty day moving average price is $249.75 and its 200-day moving average price is $219.03. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $279.40. The firm has a market capitalization of $19.18 billion, a PE ratio of 46.83, a price-to-earnings-growth ratio of 4.06 and a beta of 1.21.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PODD shares. Barclays boosted their price objective on shares of Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target for the company. Morgan Stanley raised their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Citigroup upped their target price on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Canaccord Genuity Group increased their target price on shares of Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $260.88.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of PODD. Synovus Financial Corp boosted its position in Insulet by 36.1% in the third quarter. Synovus Financial Corp now owns 2,929 shares of the medical instruments supplier’s stock valued at $682,000 after buying an additional 777 shares during the last quarter. Tidal Investments LLC lifted its stake in Insulet by 5.2% during the 3rd quarter. Tidal Investments LLC now owns 9,365 shares of the medical instruments supplier’s stock valued at $2,180,000 after acquiring an additional 466 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Insulet in the 3rd quarter valued at $114,000. Virtu Financial LLC acquired a new stake in shares of Insulet in the third quarter worth $616,000. Finally, TD Private Client Wealth LLC raised its holdings in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 56 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.